Analysts' ratings for VYNE Therapeutics (NASDAQ:VYNE) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ...
FDA places clinical hold on VYNE’s Phase 1b trial of VYN202 due to testicular toxicity seen in preclinical dog study. VYNE halts enrollment and dosing in psoriasis study; no serious adverse events ...
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago. These ...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE ...
Vyne Therapeutics Inc. VYNE shares are trading higher Monday after the company announced a private placement of $88 million and positive data from its Phase 1b trial. In addition to the $88 million ...
HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research report report published on Thursday morning,Benzinga reports. The firm currently has ...
VYNE Therapeutics (NASDAQ:VYNE) stock price predictions are heating up on Monday with one analyst setting a high goal for the company to reach. H.C. Wainwright analyst Joseph Pantginis is behind today ...
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results